For UK pharmaceutical and life sciences leaders
Patients are stopping treatment early and you have no programme to prevent it
Without a patient support programme, adherence gaps erode both outcomes and your commercial position. Commissioners are already asking for the data you cannot yet provide.
Two minutes. Solva follows up with specific patient support programme options.
The ABPI's 2024 patient support programme review found that medicines with a structured PSP achieved 28% higher 12-month adherence rates than those without, and were 40% more likely to be included in ICB commissioning decisions. PSPs also generated real-world evidence that supported NICE re-reviews in 35% of cases. (ABPI, 2024)
Frequently asked questions
Why does this problem persist?
Patient support programmes (PSPs) have become a commercial necessity for specialty medicines, particularly in oncology, immunology, and rare diseases. Commissioners increasingly require evidence of adherence support as part of their commissioning decisions, and NICE's real-world evidence requirements mean that post-launch adherence data is critical for maintaining market access. Pharma companies without a PSP are at a commercial disadvantage in both NHS and private markets, and are missing the opportunity to generate the real-world evidence needed to support future access decisions.
What is the cost of leaving it unaddressed?
A 28% improvement in adherence on a medicine with 1,000 patients at £5,000 per year generates £1.4 million in additional revenue. Designing and implementing a PSP costs £50,000 to £200,000 per year depending on scale and complexity. (ABPI, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.